• Pranjali Gupta Department of Biotechnology, Graphic Era University, Dehradun
  • Nishant Rai Department of Biotechnology, Graphic Era University, Dehradun
  • Pankaj Gautam Graphic Era University



Objective: Overexpression of AcrAB-TolC protein complex is often associated with the virulence of multidrug-resistant bacteria. Development of an
effective efflux pump inhibitors (EPI) can be a major strategy to enhance the effectivity of current antibiotics and to restrain the menace of antibiotic
resistance among bacteria. Molecular docking based assessment of anticancer drugs as EPI with comparable docking scores of known putative EPI.
Methods: Molecular docking of target proteins (AcrA, AcrB and TolC) of Escherichia coli was carried out with four putative and seven selected
anticancer drugs using iGEMDOCK software separately.
Results: All the four putative inhibitors (norepinephrine, reserpine, verapamil and trimethoprim) used in the present study binds to AcrA (−41.9
kcal/mol, −56.75 kcal/mol, −76.69 kcal/mol and −45.20 kcal/mol respectively), AcrB (−74.61 kcal/mol, −135.97 kcal/mol, −126.66 kcal/mol and
−87.57kcal/mol respectively) and TolC (−78.49 kcal/mol, −90.22 kcal/mol, −89.42 kcal/mol and −62.57 kcal/mol respectively) with high affinity and
seven drug ligands (etoposide, paclitaxel, tamoxifen, mitomycin and thalidomide, vinblastine methotrexate) showed comparable docking energies
(AcrA [−36.44 kcal/mol, −78.23 kcal/mol, −17.04 kcal/mol, −42.96 kcal/mol, −44.94 kcal/mol, −67.96 kcal/mol and −20.15 kcal/mol respectively],
AcrB [−128.11 kcal/mol, −132.86 kcal/mol, −104.85 kcal/mol, −98.91 kcal/mol, −96.47 kcal/mol, −108.79 and −106.36 kcal/mol respectively], TolC
[−68.42 kcal/mol, −88.29 kcal/mol, −64.69 kcal/mol, −68.28 kcal/mol, −59.36 kcal/mol, −77.28 kcal/mol and −74.52 respectively]) with putative
Conclusion: Paclitaxel and vinblastine showed high affinity for all units of AcrAB-TolC of E. coli.
Keywords: AcrAB-TolC, Efflux pump, Efflux pump inhibitor, Multidrug resistance, Molecular modeling and docking, Escherichia coli.

Author Biographies

Pranjali Gupta, Department of Biotechnology, Graphic Era University, Dehradun
Research Scholar
Nishant Rai, Department of Biotechnology, Graphic Era University, Dehradun
Associate Professor
Pankaj Gautam, Graphic Era University

Assistant Professor,

Department of Biotechnology


1. Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 2006;4:629-36.
2. Hughes D, Andersson DI. Selection of resistance at lethal and non-lethal antibiotic concentrations. Curr Opin Microbiol 2012;15(5):555-60.
3. Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control 2013;2:31.
4. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 2013;4(2):185-91.
5. McKenna M. Antibiotic resistance: the last resort. Nature 2013;499(7459):394-6.
6. Worthington RJ, Melander C. Overcoming resistance to ß-lactam antibiotics. J Org Chem 2013;78(9):4207-13.
7. Chollet R, Chevalier J, Bryskier A, Pagès JM. The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother 2004;48:3621-4.
8. Miller K, O’Neill AJ, Chopra I. Escherichia coli mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections. Antimicrob Agents Chemother 2004;48(1):23-9.
9. Baucheron S, Chaslus-Dancla E, Cloeckaert A. Role of TolC and parC mutation in high-level fluoroquinolone resistance in Salmonella enterica serotype Typhimurium DT204. J Antimicrob Chemother 2004;53(4):657-9.
10. Amin IM, Richmond GE, Sen P, Koh TH, Piddock LJ, Chua KL. A method for generating marker-less gene deletions in multidrug-resistant Acinetobacter baumannii. BMC Microbiol 2013;13:158.
11. Stephan J, Mailaender C, Etienne G, Daffé M, Niederweis M. Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob Agents Chemother 2004;48(11):4163-70.
12. Sahu SN, Anriany Y, Grim CJ, Kim S, Chang Z, Joseph SW, et al. Identification of virulence properties in Salmonella typhimurium DT104 using Caenorhabditis elegans. PLoS One 2013;8(10):e76673.
13. Yasufuku T, Shigemura K, Shirakawa T, Matsumoto M, Nakano Y, Tanaka K, et al. Correlation of overexpression of efflux pump genes with antibiotic resistance in Escherichia coli strains clinically isolated from urinary tract infection patients. J Clin Microbiol 2011;49(1):189-94.
14. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 2004;64(2):159-204.
15. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45(1):105-16.
16. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3(8):673-83.
17. Chiu HC, Lee SL, Kapuriya N, Wang D, Chen YR, Yu SL, et al. Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus. Bioorg Med Chem 2012;20(15):4653-60.
18. Shah Z, Mahbuba R, Turcotte B. The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile. FEMS Microbiol Lett 2013;347(1):61-9.
19. Fernando DM, Kumar A. Resistance-nodulation-division multidrug efflux pumps in gram-negative bacteria: Role in virulence. Antibioticis 2013;2:163-81.
20. Rushdy AA, Mabrouk MI, Abu-Sef FA, Kheiralla ZH, Mohamed Abdel-All S, Saleh NM. Contribution of different mechanisms to the resistance to fluoroquinolones in clinical isolates of Salmonella enterica. Braz J Infect Dis 2013;17(4):431-7.
21. Garvey MI, Piddock LJ. The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB. Antimicrob Agents Chemother 2008;52:1677-85.
22. Ughachukwu P, Unekwe P. Efflux pump-mediated resistance in chemotherapy. Ann Med Health Sci Res 2012;2(2):191-8.
23. Dinesh MF, Ayush K. Resistance nodulation-divison multidrug efflux pumps in gram-negative bacteria: Role in virulence. Antibiotics 2013;2:163-81.
24. Priyadarshini K, Aparajitha UK. Paclitaxel against cancer a short review. Med Chem 2012;2:139-41.
25. Wilstermann AM, Bender RP, Godfrey M, Choi S, Anklin C, Berkowitz DB, et al. Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. Biochemistry 2007;46:8217-25.
26. Tomasz M, Mitomycin C. small, fast and deadly (but very selective). Chem Biol 1995;2(9):575-9.
27. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6(2):404-17.
28. Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011;122(1):1-6.
29. Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 2003;79(929):127-32.
30. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001;60(1):225-32.
31. Wang Y, Bolton E, Dracheva S, Karapetyan K, Shoemaker BA, Suzek TO, et al. An overview of the pubchem bioassay resource. Nucleic Acids Res 2010;38:D255-66.
32. Singh T, Biswas D, Jayaram B. AADS – an automated active site identification, docking, and scoring protocol for protein targets based on physicochemical descriptors. J Chem Inf Model 2011;51(10):2515-27.
33. Irwin JJ, Shoichet BK. ZINC – a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005;45(1):177-82.
34. Yang JM, Chen CC. iGEMDOCK: A generic evolutionary method for molecular docking. Proteins Struct Funct Bioinf 2004;55:88-30.35. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986;234(4774):364-8.
36. Ikai A. Thermostability and aliphatic index of globular proteins. J Biochem 1980;88(6):1895-8.
37. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157(1):105-32.
38. Panigrahi SK. Strong and weak hydrogen bonds in protein-ligand complexes of kinases: a comparative study. Amino Acids 2008;34(4):617-33.
39. Kuete V, Ngameni B, Tangmouo JG, Bolla JM, Alibert-Franco S, Ngadjui BT, et al. Efflux pumps are involved in the defense of Gram-negative bacteria against the natural products isobavachalcone and diospyrone. Antimicrob Agents Chemother 2010;54(5):1749-52.
443 Views | 603 Downloads
How to Cite
Gupta, P., N. Rai, and P. Gautam. “ANTICANCER DRUGS AS POTENTIAL INHIBITORS OF AcrAB-TolC OF MULTIDRUG RESISTANT E.Coli: AN IN SILICO MOLECULAR MODELING AND DOCKING STUDY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 8, no. 1, Jan. 2015, pp. 351-8,
Original Article(s)